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Allen Carr’s Easyway to Stop Smoking - A randomised
clinical trial
Sheila Keogan, Shasha Li, Luke Clancy
Abstract
Objective To determine if Allen Carr’s Easyway to Stop
Smoking (AC) was superior to Quit.ie in a randomised
clinical trial (RCT).
Setting Single centre, open RCT, general population
TobaccoFree Research Institute
based.
Ireland, Focas Research Institute,
Participants 300 adult smokers, 18 years plus,
DIT, Dublin 8, Dublin, Ireland
minimum 5 cigarettes daily, and English speaking. AC,
151 (females 44.4%) and Quit.ie, 149 (females 45.6%),
Correspondence to
mean age 44 years. outcomes for all 300 were analysed
Professor Luke Clancy,
TobaccoFree Research Institute
(intention-to-treat). Recruited through advertisement
Ireland, Focas Research Institute, from July 2015 to February 2016.
DIT, Dublin 8, Dublin, Ireland;
Intervention Randomly assigned to AC (n=151) and 
l clancy@tri.ie
Quit.ie (n=149), matched for age, sex and education.
Block randomisation, enrolment and follow-up at 1, 3,
Received 5 January 2018
Revised 17 August 2018
6 and 12 months. Primary aim was to determine if AC
Accepted 28 August 2018
had higher quit rates than Quit.ie service at 3 months.
Secondary aims: quit rates at 1, 6 and 12 months and
analysis of associated factors including weight. AC
consisted of a 5-hour seminar, in a group setting. Quit.ie
is an online portal for smoking cessation.
Results AC had higher quit rates at 1, 3, 6 and 12
months. AC: 38%, (n=57), 27% (n=40), 23% (n=35),
22% (n=33) vs Quit.ie: 20% (n=30), 15% (n=22), 15%
(n=23), 11% (n=17), respectively (all p values <0.05).
 uit.ie, OR 2.26 (95% CI 1.22
Logistic regression AC vs Q
to 4.21) p value=0.01. Weight gain 3.8 kg in AC vs 1.8
kg in Quit.ie (p value <0.05).
Conclusions All AC quit rates were superior to 
Quit.ie, outcomes were comparable with established
interventions.
Trial registration number ISRCTN12951013.
Recruitment July 2015–February 2016.
►► Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
tobaccocontrol-2018-054243).
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Established, effective and cost-effective treatments
for tobacco dependence include brief intervention, psychological support and pharmacotherapy,
including nicotine replacement therapy (NRT),
varenicline and bupropion, which have a high level
of proven success in previous scientific studies.1–10
The success rates achieved are variable but are of
the order of 7%–31% quit at 12 months.11–13
Recently, efforts have been made to improve
the reach and impact of smoking cessation
services in Ireland including the implementation
of mobile phone, internet and social media-based
interventions.14–18
The Allen Carr method has been used for over
30 years and is available in 150 centres in over 50
different countries. The method claims to have
helped more than 30 million smokers quit, with a
90% quit rate advertised on its website.19 There has
been very little empirical research on the efficacy

of the AC method.20–22 The scientific basis of the
method is also unclear.20 AC does not include pharmacotherapy, and the behavioural intervention
does not seem to be based on the transtheoretical
model of behaviour change.19 23
In this study, we compare Allen Carr’s Easyway
to Stop Smoking (AC) with the National Online
Smoking Cessation Service, Quit.ie, in a randomised
clinical trial (RCT).

Study objectives

The objectives were: to assess the relative effectiveness of AC and Q
 uit.ie, using carbon monoxide
(CO) validated Quit status at 1, 3, 6 and 12 months
for each treatment condition, and to measure the
continuous abstinence rate using Russell standard,24
to consider non-quit outcomes and factors associated with successful quitting.

Study goals

To provide an evidence base with regard to the
efficacy of the AC method for smoking cessation
for smokers wishing to quit and also to inform
policy-makers regarding its possible suitability for
inclusion in publicly recommended smoking cessation treatment services.

Methods

This study is an open, single-centre, randomised,
superiority clinical trial with parallel group design
using Consolidated Standards of Reporting Trials
guidelines (online supplementary file 1). Patients
(n=300) were randomly assigned to either AC
condition or registered on the online Health Service
Executive (HSE) National Smoking Cessation
Service (https://www.quit.ie/).
The study protocol (online supplementary file 2)
was registered on the ISRCTN registry.

Recruitment

Smokers were recruited through public advertisement in an Irish national newspaper, and
on national and local radio in July 2015. Those
responding were directed to TobaccoFree Research
Institute Ireland (TFRI) website (www.
tri.
ie) and
asked to complete a study questionnaire on inclusion and exclusion criteria and a readiness to quit
score (online supplementary file 3).24
The inclusion criteria were that participants be
18 years or older, smoking a minimum of 5 cigarettes per day, have a good knowledge of the English
language, as AC was delivered in English, and agree
to attend all five study visits in TFRI, Dublin. Exclusion criteria were doctor-diagnosed, acute cardiac
or respiratory illness or serious psychiatric illness
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Table 1

Baseline characteristics of participants by treatment groups

Female, n (%)

Quit.ie (n=149)

AC (n=151)

68 (45.6)

67 (44.4)

Age, median (IQR)

44.0 (38.0–51.0)

44.0 (36.0–52.0)

Initial weight, median (IQR), kg

80.8 (69.0–93.9)

79.8 (69.4–91.7)

Postsecondary and higher education,
n (%)

104 (69.8)

105 (69.5)

Baseline CO reading, mean (SD), ppm

20.4 (10.5)

22.1 (11.6)

 ≤5 min

42 (28.2)

56 (37.1)

 6–30 min

66 (44.3)

61 (40.4)

 >31 min

41 (27.5)

34 (22.5)

Prior use of e-cigarettes, n (%)

72 (48.3)

75 (49.7)

 None

6 (4.2)

4 (2.7)

 1–3

63 (43.8)

69 (46.3)

 4–9

61 (42.4)

59 (39.6)

 10 and over

14 (9.7)

17 (11.4)

No of cigarettes smoked per day,
median (IQR)

20.0 (15.0–22.0)

20.0 (15.0–25.0)

How many years are you smoking,
median (IQR)

28.0 (22.0–34.0)

26.0 (20.0–35.0)

Readiness to quit score, median (IQR)

27.0 (24.5–29.0)

27.0 (25.0–29.0)

Time to first cigarette, n (%)

Previous quit attempts, n (%)

AC, Allen Carr’s Easyway to Stop Smoking; CO, carbon monoxide.

and must not be currently undergoing treatment for alcohol or
illicit drug use. A total of 3065 smokers responded, 112 did not
leave contact details, 918 were excluded on exclusion criteria.
The remaining 2035 were contacted by email on a first-comefirst-served basis; 1414 did not respond and 631 responded positively. Appointments were sent to 551 yielding 300 who met the
criteria, and were randomised; 251 did not attend as requested
and 70 were not contacted once recruitment was completed in
February 2016. Follow-up was completed in March 2017. Irish
and UK white nationals made up 90% of the sample, nine other
nationalities were represented and there was equal ethnic distribution for both conditions.

Participants completed a 5-hour, group AC seminar, maximum
20 participants, in a routine seminar session. Participants smoke
during smoking breaks until there is a ritualistic final cigarette followed by a 20 min relaxation exercise. Follow-up was
arranged at TFRI research centre for months 1, 3, 6 and 12. Two
free AC follow-ups were also available.

Quit.ie service

 uit.ie is an online portal for HSE smoking cessation services,
Q
and it is delivered free of charge.18 Quit.ie has a team of accredited National Centre for Smoking Cessation and Training
(NCSCT, UK) Tobacco Cessation Practitioners. They give
smokers information and behavioural support on the phone, by
text and online through their website and Facebook community.
As part of the Quit.ie quit plan, participants set their quit date,
requested daily support texts and or emails for 1 month and at
least two further follow-up communications and arranged to
have a counselling phone call from the quit team specialist. The
decision to use medication rested with the client, who was also
responsible for arranging the purchase or prescription of any
NRT or other medication that they used.
Participants were registered on Q
 uit.
ie during their first
TFRI visit, and an agreed quit date was set. An appointment for
follow-up was arranged at the TFRI research centre at months 1,
3, 6 and 12 following their target quit date. All registered clients
are sent an email from Quit.ie at 3 months requesting confirmation of quit status.

Follow-up visits

All randomised smokers were invited to attend an initial and
four other visits at TFRI. Self-reported quitting was recorded
and validation by CO Breath test was carried out at each visit
using a CO monitor. The monitor used in this study was the Care
fusion CO monitor.26 Other data collected included weight,
relapse information, medication used, motivational contacts
received by phone, text and email or at face-to-face meetings, if
any, or attendance at AC at each visit.

Sample size calculation

The AC condition was delivered, free of charge, by experienced
AC therapists.

The quit rates at 3 months were predicted as 25% for AC and
12% for Quit.ie. An allocation of 1:1 was selected. With 80%
power and two-sided significance level of 5%, a sample size
of 139 for each group would be needed to detect superiority
between AC and Quit.ie.
An ‘intention-to-treat’ (ITT) approach, where only CO-validated quitting, as per Russell standard is accepted as valid was
used to determine the numerator in both conditions and data
from all 300 randomised smokers (149 Quit.ie and 151 Allen
Carr) were included in the denominators for the analysis.24
Participants who were consented, randomised, set a quit date
on Q
 uit.ie or made an appointment for an AC seminar were
included in the ITT analysis. All missing quit data were regarded
as being due to failure to quit smoking even if the participants
were lost to follow-up.
A complete case analysis (CCA) approach based on both
CO-validated quitting (Russell Standard) and self-reported quitting was subsequently used to examine the difference in the
retention rate in the two conditions and reassure that failure to
return for follow-up in person was indicative of failure to quit in
this trial. Subjects who did not attend for follow-up in person,
but responded to contact by email/text/phone and self-reported
on their quit status were combined with those who had attended
in person to form the CCA samples.
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Randomisation

Block randomisation was used to reduce bias and achieve balance
in the allocation of participants to the treatment arms.25 Randomisation was performed by TFRI from July 2015 to February
2016. Participants were randomised by submitting details of
their gender, age and highest education level reached that is,
primary, secondary or third level, resulting in eight blocks and
consented participants within each block were then randomly
assigned to either the AC or the Q
 uit.ie condition.
Participants were told that those who attended all four
follow-up visits would be entered into a prize draw for 2-week
holiday, a weekend holiday and an iPad.
Randomised participants were given a unique participant
identifier code. All participant and project data were deidentified and stored on a secured password-protected server. Of the
300 enrolled, 151 smokers were allocated to AC arm and 149 to
Quit.ie (table 1).

Details of treatment conditions
Allen Carr’s Easyway to Stop Smoking
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The CCA numerators for quit rates, when accepting self-report as quit, were the sums of self-reported quit data collected
from those who attended in person and quit data from non-attenders who responded to electronic contact. The CCA numerator, when using CO-valditated quitting, can only be based on
those who attended in person. This may be clinically misleading
as it demands omitting self-reported quitting but is included
for completeness. The denominators in CCA consisted of those
for whom data were furnished in contrast to the ITT approach
where all subjects in the trial were retained in the denominator
even if lost to follow-up. For comparison, an ITT analysis using
self-report quit rates was also performed.

Statistical analysis

Analysis of variance test was used to test if participants’ categorical characteristics were balanced between the two conditions.
Two-sided two-sample mean tests were carried out for continuous characteristics. In addition, as it was a superiority clinical
trial, two-sample one-tailed proportion tests were carried out
when comparing quit rates and retention rates between the two
trial groups, and when comparing treatment effects in Quit.ie.
Two-sample mean tests were used to compare weight gain.
The dichotomous primary outcomes were analysed via multivariable logistic regression. The independent variables included
were trial group, gender, education, age, prior use of e-cigarettes, baseline CO reading, time to first cigarette, readiness to
quit score and previous quit attempt. Univariable logistic regressions were carried out to measure the impact on quit outcome of
taking cigarette puffs between visits. Significance level of all tests
was set to 0.05. All analyses were performed using IBM SPSS
Statistics for Windows V.24.

Results

Χ2 test and two-sample proportion z test showed that AC was
superior to Quit.ie. At each visit, the quit rate in the AC group
is significantly greater than that of the Q
 uit.ie group using ITT
Co-validated quitting (table 2). The difference between the two
groups was strongest at the 1-month follow-up visit and remained

Table 2
Method
ITT

Quit rates based on ITT and CCA for AC and Quit.ie: Using Russell Standard (CO validated) quitting and self-report quitting
Quitting
definition
Russell
Standard

Self-report

CCA

statistically significant at 3, 6 and 12-month follow-ups, in each
of which, quit rates in the AC group were almost twice that of
the Q
 uit.ie. Table 2 shows that in the AC condition, the quit rate
decreased from 37.7% (n=57) at 1 month to 21.9% (n=33) at
12 months (p=0.001) while in Quit.ie, the quit rate decreased
from 20% (n=30) at 1 month to 11.4% (n=17) at the 12 months
(p=0.02).
Using CCA and CO-validated quitting, where the quitting rate
in AC was nearly twice as great as Q
 uit.ie, the difference was not
statistically significant.
It was assumed in ITT that non-attenders had mainly failed to
quit, no such assumption was made for CCA and that seemed to
account for the difference in attendance in this trial.
However, using data collected from non-attenders and
accepting self-report as quit for ITT and CCA, the results were
similar to CO-validated quitting ITT with an even greater superiority for AC and suggesting that failure to attend was not
attributable to the condition (table 2) and that the worst case
assumption of CO-validated quitting was not misleading.
The relapse rates were not significantly different between
Quit.ie and AC condition at the 1, 3, 6 or 12 month visits.
Multivariate logistic regression of 3-month outcomes
included: trial group, gender, education, age, prior use of E-cigarettes, baseline CO reading, time to first cigarette, readiness to
quit score and previous quit attempts. Three significant variables
were found: trial group, education and baseline CO.
Being in the AC condition increased the odds of quitting by 2.3
(95% CI 1.2 to 4.2) compared with being in Quit.ie condition.
Education and baseline CO level were also significant factors
associated with an increased likelihood of quitting at 3-month
follow-up (table 3).
In sensitivity analysis, CO readings were replaced by the
number of cigarettes smoked per day; this was not found to be
significant. The number of years’ participants were smoking
was not included as the correlation of number of years smoking
with age was too strong. Time to first cigarette variable had two
missing values, and previous quit attempt variable had seven
missing values. Therefore, the total number of observations used

Russell
Standard

Self-report

Quit.ie

AC

Month

No of quitters

Sample size

Quit rate

No of quitters

Sample size

Quit rate

P values*

1

30

149

20.1%

57

151

37.7%

<0.001†

3

22

149

14.8%

40

151

26.5%

0.006†

6

23

149

15.4%

35

151

23.2%

0.045†

12

17

149

11.4%

33

151

21.9%

0.008†

1

36

149

24.2%

63

151

41.7%

<0.001†

3

26

149

17.5%

48

151

31.8%

0.002†

6

25

149

16.8%

42

151

27.8%

0.011†

12

21

149

14.1%

36

151

23.8%

0.016†

1

30

69

43.5%

57

110

51.8%

0.139

3

22

46

47.8%

40

81

49.4%

0.433

6

23

41

56.1%

35

72

48.6%

0.778

12

17

38

44.7%

33

63

52.4%

0.228

1

36

124

29.0%

63

134

47.0%

0.002†

3

26

114

22.8%

48

130

36.9%

0.008†

6

25

108

23.1%

42

120

35.0%

0.025†

12

21

105

20.0%

36

107

33.6%

0.013†

*The alternative hypothesis is that AC has a higher quit rate than Quit.ie.
†The test is significant at 0.05 level.
AC, Allen Carr’s Easyway to Stop Smoking; CCA, complete case analysis; CO, carbon monoxide; ITT, intention-to-treat.
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Table 3

Logistic regression of 3-month outcome
95% CI for OR
P values

OR

Lower

Upper

AC (vs Quit.ie)

0.01

2.26

1.22

4.21

Female (vs male)

0.94

1.03

0.55

1.92

Higher (vs lower) education

0.002

3.62

1.58

8.28

Age

0.89

1.00

0.97

1.04

Prior use of e-cigarette (vs non-use)

0.93

0.97

0.52

1.82

Baseline CO reading

0.005

0.96

0.92

0.99

Time to first cigarette (vs ≤5 min)

0.42

 6–30 min

0.19

0.61

0.29

1.28

 >31 min

0.61

0.80

0.35

1.86

Readiness to quit score

0.95

1.00

0.91

1.09

Previous attempts to quit (vs none)

0.10

 1–3

0.51

2.11

0.23

19.01

 4–9

0.33

2.90

0.32

26.33

 10+

0.11

6.72

0.66

68.22

Constant

0.16

0.07

AC, Allen Carr’s Easyway to Stop Smoking; CO, carbon monoxide.

in the final regression was 291 instead of 300. Regressions were
also run for 1 month, 6 months and 12 months. Trial group and
education remained significant for all months. CO level was
significant at 1 and 6 months but not at 12 months.
Smokers with higher education had 3.6 (95% CI 1.6 to 8.3)
times’ greater odds of quitting than those with lower education
(table 3). The quit rate was greater in the AC higher education
group at each month and statistically significant at 1, 3 and 12
months. For people with lower education, the quit rate was
also greater in the AC group at each month, but the numbers
in this category were small and did not reach statistical significance (table 4). There was a lower number of those with a lower
education recruited, n=92 versus higher educated n=209, at
least partially explained by completion rates for second-level
education in Ireland of 91%.27
A 1-unit increase in baseline CO reading was associated with
95.5% (95% CI 92% to 99%) lower odds of quitting. Variables
to measure the extent of addiction, before participants started
the trial, were: how soon after waking they had their first cigarette, years of smoking and the number of cigarettes smoked per
day.28 After replacing the CO reading variable by the alternatives
one at a time, the alternatives were not significant at 0.05 levels
while trial groups and education remained significant.
All participants were asked to self-report their quit status
at each visit, and breath CO tests were performed. Nobody
in either condition self-reporting quit at 3 months had a CO
reading >5. In the Q
 uit.ie condition, one participant reporting
quit at 12 months had a CO reading of >10. In the AC condition, one participant who reported quit at 12 months had a CO
reading between 6 and 10 recorded.
Table 4
group

Quit rates and number of quitters by education and trial

AC higher
Months of
trial
 N (%)

Quit.ie higher

AC lower

Quit.ie lower

N (%)

N (%)

N (%)

1

45 (43)

27 (26)

12 (26)

3 (7)

3

34 (32)

20 (19)

6 (13)

2 (4)

6

29 (28)

20 (19)

6 (13)

3 (7)

12

27 (26)

15 (14)

6 (13)

2 (4)

AC, Allen Carr’s Easyway to Stop Smoking.

4

The relationship between having taken a ‘single puff ’ between
quit date and 1 month and quit outcome at subsequent visits
was also examined combining both trial groups. Univariable
logistic regressions were carried out and were significant at both
3-month and 6-month visits. People who had quit at 1 month
who had not taken a single puff (n=65) between quit date and
1 month had a 3.9 (95% CI 1.4 to 11.2) times greater odds of
quitting at 3 months (n=47) than those who had taken a puff at
1 month (n=20) and had quit at 3 months (n=10).
All participants attending the AC condition were instructed
not to take any form of pharmacotherapy to aid quitting. Therefore, when considering the pharmacotherapeutic agents used
for quitting, other than e-cigarettes, we examined only Q
 uit.ie.
This showed: NRT (n=42, various formulations), varenicline
(n=14) and none (n=14). Those who took varenicline between
quit date and 3 months had a significantly higher quit rate at 3
months than both those who took nothing (p=0.003) and those
who took NRT (p=0.005). There was no statistically significant
difference in quit outcome at 3 months between those using
none and those using NRT (p=0.36).
A number of participants used e-cigarettes at some stage
between quit date and 3 months, (n=15) in Quit.ie and (n=12)
in the AC condition. E-cigarettes were not found to significantly
affect the quit outcome at 3 months in AC group. In Q
 uit.ie
condition, people who used e-cigarettes before the 3-month visit
achieved a lower quit rate at 3 months (3 out of 15) than those
who did not use e-cigarettes (19 out of 35) (p=0.01). This result
may be due to the small number of observations in Q
 uit.ie.
Successful quitters gained weight in both study conditions.
There were three pregnant women in the study, two in AC group
and one in Quit.ie. There were two participants who had serious
illnesses and received medical intervention during the study. As
fluctuations in weight could not be attributed to quitting, all five
were removed from the weight analysis.
Absolute weight gains: The mean weight gain for quitters at 3
months in AC was 3.8 kg vs 1.8 kg in Quit.ie, the mean weight
gain at 12 months in the AC was 5.02 kg vs 3.18 kg in Q
 uit.ie.
The mean weight gain was statistically greater in AC than Q
 uit.
ie at 1, 3 and 6 months (p=0.003 for 1 month, p=0.008 for 3
months, p=0.02 for 6 months), but not at 12 months (p=0.15).
Of the 300 participants randomised, the numbers retained at
1, 3, 6 and 12 months were 179, 127, 113 and 101 participants,
respectively. The retention rate was significantly higher in the
AC group than that in the Q
 uit.ie group at each follow-up visit
(p<0.001 at 1, 3 and 6 months, p=0.002 at 12 months). To
get further information on the quit rates including non-attenders
at clinic follow-up, all participants who did not attend at each
month were contacted by email or by phone, if no email address
was available. A CCA was then performed on the total sample
with quit data at 1 month, 258 total (124 Quit.ie vs 134 AC), at
3 months 244 (114 Quit.ie vs 130 AC), at 6 months 228 (108
Quit.ie vs 120 AC) and at 12 months 212 (105 Q
 uit.ie vs 107
AC). This analysis showed that AC was statistically superior at
each month, with p value at 0.002, 0.008, 0.025 and 0.013 at 1,
3, 6 and 12 months, respectively (see online online supplementary file 4).
The only reported adverse effect was one person in the AC
treatment who went to see her doctor because of withdrawal
symptoms.

Discussion

In this RCT, AC—a non-pharmacotherapeutic one-off seminar-based intervention—had a quit rate which was superior to
Keogan S, et al. Tob Control 2018;0:1–6. doi:10.1136/tobaccocontrol-2018-054243
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an online comprehensive national smoking cessation service
consisting of advice by telephone, texts and email, supported by
a dedicated website and Facebook community.
The short-term and long-term cessation CO-validated quit
rates of AC exceeded those of Q
 uit.ie by a factor of nearly two
at all the time points tested on an ITT basis. The mechanism of
this effect is unclear. There is some suggestion that the seminar
is based on an expectancy challenge as has been used in alcohol
treatment and consideration of these types of interventions seem
to be similar to the AC approach.20 29–31 Being told that all AC
therapists have used the method to stop smoking themselves,
the widespread celebrity endorsements, and the popularity of
the Allen Carr book may also be factors. The recent RCT of
the Allen Carr book does not seem to support this latter suggestion.32 It specifically does not seem to be based on motivational
behavioural change, and smoking cessation pharmacotherapy is
not allowed or suggested even for control of withdrawal symptoms. No apps, texts or phone calls or social media community
are prescribed in AC. The results achieved with AC, 26% quit at
12 months, are similar to the estimates for UK national smoking
cessation service for varenicline with specialist individual
behavioural support at a specialist clinic.(13) The results achieved
with Q
 uit.ie at 11% at 12 months are similar to UK national
smoking cessation service with Mono NRT with specialist
drop-in behavioural support.1 13
The outcomes in Quit.ie are comparable with results observed
with individual elements of successful interventions of internet,
telephone support, emails and social media. Perhaps Q
 uit.ie may
be improved by increased use of proven evidence-based medication and face to face consultations. 17 33
This RCT was limited to well people and although there was
no age restriction in the protocol, it did not have very many
young adults or older people who may have a lower quit rate but
this did not seem to increase the quit rate in the well-matched
Quit.ie condition. Our inability to explore possible mechanisms
of action of AC and the training of AC therapists and not to be
able to tailor Quit.ie content precisely creates a limitation to full
understanding of the conditions but does not account for the
superiority of the AC condition. For instance, face-to-face interactions were possible in the Quit.ie service but must be requested
by the participant and they were not requested. Also pharmacotherapy was recommended in Quit.ie but was underused within
the programme by trial participants. Changes have been made to
formalise the interventions in the Quit.ie service.
The retention rate was low, particularly in the Q
 uit.ie condition and may have been partially influenced by the absence
of personal contact. Electronic follow-up of clinic defaulters
confirmed a lower self-reported quit rate in Quit.ie. The resulting
CCA analysis gave similar results to the ITT approach suggesting
that the poor retention rate was not particular to either condition and did not materially affect the results.
One person in the AC condition developed significant withdrawal symptoms which led her to visit her doctor. Otherwise,
AC was very well tolerated, making it particularly suitable for
smokers unwilling or unable to tolerate pharmacotherapy. Pregnancy is also a condition where AC would seem particularly
suitable, where reluctance to take medication is very strong.34 35
Young people who also have a low uptake of present services may
be interested in the AC method.36–38 These are populations not
addressed in this trial but would seem worthy of further exploration. It is clear however that it is suitable for well, middle-aged
smokers of both sexes.
There is widespread acceptance by the public of the efficacy
of AC as evidenced by the numbers who have used the service at
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their own expense and its widespread use in corporate settings
for smoking cessation but, to the best of our understanding, it is
not employed by any public health agency providing a smoking
cessation service.19 The previous lack of RCT evidence showing
efficacy may be the reason funding authorities both public and
private seem reluctant to offer AC. The present RCT is positive
and should encourage further trials and increase the likelihood
that AC will take its place as a valid, effective and needed addition to available smoking cessation interventions.

What this paper adds
►► The Allen Carr book is said to have sold some 13 million

copies and have helped people stop smoking.

►► There are a large number of celebrity endorsements testifying

to the merits of Allen Carr’s method but very few trials of any
kind and very few publications of outcomes.
►► No randomised clinical trials of Allen Carr’s Easyway to Stop
Smoking were published before this trial.
►► This study shows that Allen Carr’s Easyway to Stop Smoking
was superior to a standard online National Smoking
Cessation in a Randomised Clinical Trial.
►► It was free of any serious side effects.
►► As a once-off seminar, where pharmacotherapy is not used,
it seems highly appropriate to consider it as an acceptable
method for smoking cessation.
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